A study in anaesthetised dogs aged 2, 6, 13,26 and 52 weeks or older was done to determine the dose of IV bupivacaine given by infusion required to produce severe cardiovascular depression as measured by a drop in mean blood pressure to about 25 mmHg or the development of lifethreatening dysrrhythmias. Plasma local anaesthetic concentration was analysed at the time of ceasing the infusion. The toxic dose was significantly less in the six-week-old group than younger or older animals. The plasma concentrations associated with toxicity in the groups 13 weeks and younger were significantly lower than in the older dogs. Treatment of the induced toxicity included hyperventilation, adrenaline infusion, bretylium and/or cardioversion. The response to treatment was better in young dogs than adult dogs.
cardiovascular toxicity but prompt treatment usually produces an uneventful recovery.
Toxic doses and plasma levels of bupivacaine in infants and children have not been determined. Because of the physiological differences between neonates and older subjects there may be some differences in toxicity. 4 This study in puppies and young dogs was designed to analyse: 1. the possible relationships between age, toxic dose and plasma bupivacaine levels; and 2. to test a protocol of treatment that could be useful in correcting the cardiac depression.
As children usually receive nitrous oxide, oxygen and halothane while having a local block, these drugs were included in the protocol so that the experimental and clinical conditions were similar.
MATERIALS AND METHOD
Mongrel puppies were anaesthetised with nitrous oxide and halothane using a mask induction, their trachea intubated and ventilation controlled to maintain an endtidal C02 of about 35 mmHg measured with a DA TEX capnograph. A femoral artery cannula was inserted percutaneously or by cutdown for sampling and blood pressure monitoring. A catheter in the superior vena cava was used for the administration of fluids and drugs and for central venous pressure measurement.
ECG (lead 2), blood pressure and central venous pressure were monitored using an Electronics for Medicine Multichannel Cardiac Monitor. Ventilation was controlled using a Loosco ventilator for small puppies and a Starling pump for older dogs.
The same group of dogs was studied on five occasions at about two weeks (9-21 days), six weeks (5-7 weeks), three months (12-14 weeks), six months (23-26 weeks) and over one year of age (Table 1) .
A total of 40 trials were done but only 35 sets of results were included in the analysis since in five the data was incomplete.
After a period of stabilisation during which Hartmann's solution 10 mllkg was infused, an infusion of bupivacaine 1.0 mg/kg/min was given until the mean arterial pressure dropped to about 25 mmHg or significant ventricular dysrrhythmias developed.
Arterial samples for measurement of plasma bupivacaine concentrations were taken every two minutes and when the infusion was ceased. Arterial blood gases and electrolytes were checked before the infusion was begun, at the time of ceasing the infusion and then as required during the resuscitation.
Bupivacaine concentration was measured using high performance liquid chromatography.
When the infusion was stopped a resuscitation protocol was initiated consisting of: -hyperventilation with 100% oxygen, -bicarbonate 1.0 mmollkg, -adrenaline infusion starting with 0.1 llg/kg/min, -intravenous fluid load 10 mllkg, and when ventricular arrhythmias were present: -bretylium 5 mg/kg, -cardioversion 2 joules/kg.
Statistics
Multiple regression analysis and t-test analysis was done using the SIST AT computer package. Table  mean age, mean weight, and mean heart rate and mean arterial pressure at the time of ceasing the bupivacaine infusion are presented as well as the standard deviations.
RESULTS

In
In Table 2 the mean bupivacaine dose in each age group when the infusion was stopped is given, as well as the corresponding plasma bupivacaine concentration. Figures 1 and 2 show the toxic doses and corresponding plasma concentrations at the cessation of the infusion for each age group.
The plasma concentrations associated with the defined degree of cardiovasular depression was lowest in the six-week-old puppies compared with all other groups but not significantly different from the two-and 13-week-old groups. When all puppies aged 13 weeks or less are compared with dogs older than 26 weeks there was a significant difference (P < 0.05).
Dysrrhythmias
Dogs in all groups developed sinus bradycardia followed by conduction blocks of different degrees. Ventricular dysrrhythmias were present in three out of 35 experiments at the time of ceasing the infusion of bupivacaine.
The haemodynamics improved in all dogs after treatment was initiated, particularly with the infusion of adrenaline up to 15 Ilg/kg/min, although ventricular tachycardia or frequent extrasystoles occurred on nine occasions (28%). Spontaneous reversion occurred after 10 to 15 seconds of dysrrhythmia in the puppies but three adult dogs required treatment for persistent venticular dysrrhythmias. One responded well to one intravenous dose of bretylium 5 mg/kg. 5 The remaining two died of intractable ventricular fibrillation despite several doses of bretylium and attempts at cardioversion. In general the response to resuscitation was better in puppies than adult dogs.
DISCUSSION
The dose required to produce the same degree of cardiovascular depression was. found to be significantly lower in the six-weekold group than in younger or older animals (P < 0.05). There was no significant correlation between toxic dose and age. The lower dose required at six weeks of age may be due to the lower plasma protein concentration in young animals,6,7 resulting in less protein binding ofbupivacaine. A further study is needed to determine the influence of plasma protein binding at different ages.
It has also been observed that peak plasma concentrations are attained earlier in the young, when cardiac output is higher.
Intractable ventricular dysrrhythmias are the most severe toxic problem with bupivacaine in awake patients. 8 Bupivacaine makes the conducting tissue refractory periods asynchronous. 9 High levels of endogenous cathecolamines induced by stress or convulsions can cause re-entry phenomena. There is a suggestion that stimulation of the central nervous system by bupivacaine can activate localised ventricular tissue through an increase in sympathetic outflow to the heart. IQ The infrequent triggering of ventricular dysrrhythmias during the infusion of bupivacaine in this study may be due to decreased release of endogenous catecholamines while the animal is anaesthetised. The potential for developing ventricular dysrrhythmias after high doses of bupivacaine in apprehensive subjects is demonstrated by the appearance of ventricular dysrrhythmias after the administration of adrenaline.
Treatment with adrenaline in high doses counteracted the cardiac depression produced by bupivacaine",12 but its administration should be carefully titrated in an infusion to avoid the development or worsening of ventricular dysrrhythmias. Boluses of adrenaline increase the severity of dysrrhythmias.
Hyperventilation to produce mild hypocarbia (30-35 mmHg) may reduce the non-ionised fraction of bupivacaine. '3 ,'4 Correction of acid-base disturbances is an integral part of the successful management of bupivacaine-induced cardiac depression. If cardiac arrest occurs prolonged cardiopulmonary resuscitation may be Anaesthesia and Intensive Care, Vol. 15, No. 4, November, 1987 necessary because of the high affinity of bupivacaine for the cardiac tissue.
